 Michael McDermott
Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperthyroidism | 5 | 2020 | 23 | 1.680 |
Why?
| | Hypothyroidism | 5 | 2020 | 72 | 1.580 |
Why?
| | Thyroid Neoplasms | 3 | 2020 | 337 | 0.790 |
Why?
| | Graves Disease | 2 | 2020 | 34 | 0.730 |
Why?
| | Osteoporosis | 5 | 2009 | 243 | 0.710 |
Why?
| | Triiodothyronine | 3 | 2020 | 43 | 0.710 |
Why?
| | Iodine Radioisotopes | 5 | 2020 | 145 | 0.650 |
Why?
| | Thyroxine | 3 | 2020 | 62 | 0.630 |
Why?
| | Bone Density Conservation Agents | 2 | 2009 | 80 | 0.560 |
Why?
| | Thyroid Diseases | 4 | 2005 | 36 | 0.560 |
Why?
| | Thyrotropin | 5 | 2020 | 114 | 0.550 |
Why?
| | Thyrotoxicosis | 2 | 2020 | 9 | 0.530 |
Why?
| | Vitamins | 2 | 2008 | 186 | 0.500 |
Why?
| | Antithyroid Agents | 4 | 2020 | 13 | 0.500 |
Why?
| | Vitamin D | 3 | 2008 | 397 | 0.490 |
Why?
| | Hypoglycemic Agents | 2 | 2016 | 1283 | 0.480 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2023 | 2516 | 0.410 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2012 | 45 | 0.380 |
Why?
| | Vitamin D Deficiency | 3 | 2009 | 186 | 0.360 |
Why?
| | Diagnosis, Differential | 4 | 2020 | 1484 | 0.340 |
Why?
| | Cardiovascular Diseases | 2 | 2023 | 2113 | 0.310 |
Why?
| | Self Administration | 2 | 2025 | 123 | 0.300 |
Why?
| | Premenopause | 1 | 2009 | 131 | 0.290 |
Why?
| | Patient Education as Topic | 2 | 2015 | 762 | 0.280 |
Why?
| | Thyroidectomy | 2 | 2020 | 106 | 0.250 |
Why?
| | Endocrinology | 2 | 2004 | 79 | 0.250 |
Why?
| | Thyroid Hormones | 2 | 2020 | 61 | 0.250 |
Why?
| | Pharmacists | 1 | 2008 | 260 | 0.240 |
Why?
| | Hormone Replacement Therapy | 2 | 2020 | 96 | 0.230 |
Why?
| | Adrenal Insufficiency | 1 | 2025 | 31 | 0.230 |
Why?
| | Bone Density | 4 | 2009 | 487 | 0.230 |
Why?
| | Blood Glucose | 3 | 2023 | 2182 | 0.220 |
Why?
| | Humans | 32 | 2025 | 137294 | 0.210 |
Why?
| | Reproductive Medicine | 1 | 2004 | 15 | 0.210 |
Why?
| | Hospitalization | 2 | 2020 | 2214 | 0.210 |
Why?
| | Professional Practice | 1 | 2003 | 64 | 0.210 |
Why?
| | Thyrotropin, beta Subunit | 1 | 2002 | 5 | 0.200 |
Why?
| | Hydrocortisone | 1 | 2025 | 323 | 0.200 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1063 | 0.190 |
Why?
| | Whole-Body Counting | 1 | 2002 | 6 | 0.190 |
Why?
| | Thyroglobulin | 1 | 2002 | 27 | 0.190 |
Why?
| | Point Mutation | 1 | 2002 | 235 | 0.190 |
Why?
| | Diabetes Mellitus | 2 | 2008 | 1036 | 0.180 |
Why?
| | Diet | 2 | 2023 | 1275 | 0.180 |
Why?
| | Thyroid Gland | 1 | 2002 | 94 | 0.180 |
Why?
| | Hip Fractures | 1 | 2003 | 99 | 0.180 |
Why?
| | Insulin | 2 | 2016 | 2406 | 0.180 |
Why?
| | Methimazole | 1 | 2020 | 6 | 0.180 |
Why?
| | Myxedema | 1 | 2020 | 1 | 0.170 |
Why?
| | Glucocorticoids | 1 | 2025 | 596 | 0.170 |
Why?
| | Absorptiometry, Photon | 3 | 2009 | 254 | 0.160 |
Why?
| | Treatment Failure | 1 | 2020 | 354 | 0.160 |
Why?
| | Female | 18 | 2025 | 73052 | 0.150 |
Why?
| | Physical Examination | 1 | 2020 | 243 | 0.150 |
Why?
| | Triiodothyronine, Reverse | 1 | 2018 | 2 | 0.150 |
Why?
| | Thyroid Function Tests | 1 | 2018 | 14 | 0.150 |
Why?
| | Reference Values | 1 | 2020 | 818 | 0.150 |
Why?
| | Risk Factors | 5 | 2020 | 10368 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1577 | 0.150 |
Why?
| | Mass Screening | 3 | 2020 | 1268 | 0.140 |
Why?
| | Practice Patterns, Physicians' | 2 | 2006 | 1302 | 0.140 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2020 | 323 | 0.140 |
Why?
| | Hypoglycemia | 2 | 2016 | 443 | 0.140 |
Why?
| | Parathyroid Hormone | 2 | 2008 | 108 | 0.130 |
Why?
| | Insulin Antibodies | 1 | 2016 | 105 | 0.120 |
Why?
| | Biomarkers | 2 | 2020 | 4164 | 0.120 |
Why?
| | Pregnancy Complications | 1 | 2020 | 525 | 0.120 |
Why?
| | Rituximab | 1 | 2016 | 178 | 0.120 |
Why?
| | Referral and Consultation | 1 | 2020 | 778 | 0.110 |
Why?
| | Aged | 10 | 2025 | 23851 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1058 | 0.110 |
Why?
| | Immunologic Factors | 1 | 2016 | 237 | 0.110 |
Why?
| | Ambulatory Care | 2 | 2008 | 539 | 0.100 |
Why?
| | Diabetes Complications | 1 | 2015 | 226 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2020 | 3546 | 0.100 |
Why?
| | Body Composition | 2 | 2023 | 678 | 0.100 |
Why?
| | Pregnancy | 3 | 2020 | 6743 | 0.100 |
Why?
| | Thyroid Crisis | 1 | 2012 | 8 | 0.100 |
Why?
| | Sex Factors | 2 | 2012 | 2073 | 0.100 |
Why?
| | Age Factors | 2 | 2012 | 3297 | 0.100 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 460 | 0.090 |
Why?
| | Postpartum Thyroiditis | 1 | 2011 | 1 | 0.090 |
Why?
| | Obesity | 3 | 2023 | 2983 | 0.090 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2015 | 279 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2008 | 7607 | 0.090 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 574 | 0.090 |
Why?
| | Drug Interactions | 1 | 2012 | 406 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2020 | 15639 | 0.080 |
Why?
| | Risk | 1 | 2012 | 908 | 0.080 |
Why?
| | Male | 11 | 2025 | 67560 | 0.080 |
Why?
| | Liver Diseases | 1 | 2012 | 311 | 0.080 |
Why?
| | Adipokines | 1 | 2009 | 49 | 0.080 |
Why?
| | Colorado | 4 | 2009 | 4527 | 0.080 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 98 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2012 | 406 | 0.070 |
Why?
| | Raloxifene Hydrochloride | 1 | 2008 | 15 | 0.070 |
Why?
| | Patient Care | 1 | 2008 | 110 | 0.070 |
Why?
| | Pharmaceutical Services | 1 | 2008 | 83 | 0.070 |
Why?
| | Diphosphonates | 1 | 2008 | 66 | 0.070 |
Why?
| | Professional Role | 1 | 2008 | 165 | 0.070 |
Why?
| | Pilot Projects | 2 | 2009 | 1700 | 0.060 |
Why?
| | Nutrition Policy | 1 | 2007 | 61 | 0.060 |
Why?
| | Insulin Lispro | 1 | 2006 | 39 | 0.060 |
Why?
| | Phosphorus | 1 | 2007 | 97 | 0.060 |
Why?
| | Nonprescription Drugs | 1 | 2007 | 66 | 0.060 |
Why?
| | Life Style | 1 | 2009 | 488 | 0.060 |
Why?
| | Serum Albumin | 1 | 2007 | 150 | 0.060 |
Why?
| | Middle Aged | 7 | 2025 | 33310 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1327 | 0.060 |
Why?
| | Women's Health | 1 | 2009 | 370 | 0.060 |
Why?
| | Creatinine | 1 | 2007 | 499 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 5769 | 0.060 |
Why?
| | Quality of Health Care | 1 | 2009 | 635 | 0.060 |
Why?
| | Patient Compliance | 1 | 2008 | 577 | 0.060 |
Why?
| | Outpatients | 1 | 2007 | 394 | 0.050 |
Why?
| | Fractures, Bone | 1 | 2009 | 420 | 0.050 |
Why?
| | Densitometry | 1 | 2003 | 36 | 0.050 |
Why?
| | Thyroid Nodule | 1 | 2003 | 56 | 0.050 |
Why?
| | Hospitals, University | 1 | 2003 | 183 | 0.050 |
Why?
| | Ossification, Heterotopic | 1 | 2002 | 16 | 0.050 |
Why?
| | Health Services for the Aged | 1 | 2003 | 80 | 0.050 |
Why?
| | Medical Records | 1 | 2003 | 174 | 0.050 |
Why?
| | Dietary Proteins | 1 | 2023 | 135 | 0.050 |
Why?
| | Inpatients | 1 | 2006 | 503 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2002 | 118 | 0.050 |
Why?
| | Biopsy, Needle | 1 | 2002 | 189 | 0.050 |
Why?
| | Exons | 1 | 2002 | 351 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 1042 | 0.040 |
Why?
| | Calcium | 1 | 2007 | 1198 | 0.040 |
Why?
| | Cattle | 1 | 2023 | 981 | 0.040 |
Why?
| | Calcinosis | 1 | 2002 | 235 | 0.040 |
Why?
| | Adult | 5 | 2025 | 37724 | 0.040 |
Why?
| | Prevalence | 1 | 2007 | 2715 | 0.040 |
Why?
| | Adenoma | 1 | 2002 | 231 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2009 | 5436 | 0.040 |
Why?
| | Base Sequence | 1 | 2002 | 2182 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2008 | 5125 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2147 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1354 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2904 | 0.040 |
Why?
| | Weight Loss | 1 | 2023 | 779 | 0.040 |
Why?
| | Exercise | 1 | 2009 | 2045 | 0.030 |
Why?
| | Risk Assessment | 1 | 2006 | 3439 | 0.030 |
Why?
| | Patient Discharge | 1 | 2003 | 906 | 0.030 |
Why?
| | Lung Diseases | 1 | 2002 | 769 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2002 | 1274 | 0.030 |
Why?
| | Prospective Studies | 1 | 2007 | 7595 | 0.030 |
Why?
| | Algorithms | 1 | 2002 | 1692 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 638 | 0.020 |
Why?
| | Resistin | 1 | 2009 | 11 | 0.020 |
Why?
| | Biological Factors | 1 | 2009 | 39 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2009 | 2836 | 0.020 |
Why?
| | Medical Audit | 1 | 2008 | 80 | 0.020 |
Why?
| | Leptin | 1 | 2009 | 236 | 0.020 |
Why?
| | Hip Joint | 1 | 2009 | 173 | 0.020 |
Why?
| | Adiponectin | 1 | 2009 | 244 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 2009 | 246 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2015 | 1203 | 0.020 |
Why?
| | Body Mass Index | 1 | 2015 | 2373 | 0.020 |
Why?
| | Program Evaluation | 1 | 2008 | 891 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1242 | 0.010 |
Why?
| | Review Literature as Topic | 1 | 2002 | 74 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 10800 | 0.010 |
Why?
| | Animals | 1 | 2023 | 36862 | 0.010 |
Why?
| | Lung | 1 | 2009 | 4067 | 0.010 |
Why?
|
|
McDermott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|